LivaNova (LIVN) Stock Price, News & Analysis

Company Overview

LivaNova plc is a global medical technology company specializing in cardiovascular and neuromodulation solutions. Through its Cardiopulmonary segment, LivaNova offers a comprehensive portfolio of products designed for use in cardiac surgery and extracorporeal circulation. Key offerings include heart-lung machines, oxygenators, autotransfusion systems and proprietary mechanical circulatory support devices that aid clinicians in complex procedures such as cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO).

In its Neuromodulation segment, LivaNova develops and markets the VNS Therapy System, an implantable device that delivers targeted vagus nerve stimulation for the treatment of drug-resistant epilepsy and depression. The company’s neuromodulation therapies build on decades of clinical research, providing physicians with an alternative approach to patients who have not responded adequately to pharmaceuticals.

Formed in 2015 through the merger of Sorin Group and Cyberonics, LivaNova combines a rich heritage of innovation dating back to the 1950s with a forward-looking focus on next-generation medical technologies. Headquartered in London, the company maintains research, development and manufacturing operations across Europe, North America and the Asia-Pacific region, serving customers in over 100 countries.

Under the leadership of President and CEO Tony Milner, LivaNova continues to expand its global footprint and invest in clinical studies and device enhancements. The company’s strategic priorities include broadening its product portfolio, strengthening regulatory partnerships and driving adoption of its advanced therapies to improve patient outcomes worldwide.

Key Stats

• Today's Range: $45.89 to $46.50
• 50-Day Range: $35.10 to $47.60
• 52-Week Range: $32.48 to $57.35
• Volume: 243,250 shs
• Average Volume: 638,315 shs
• Market Capitalization: $2.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.29
• Consensus Rating: Buy

LivaNova Stock Analysis - MarketRank™

LivaNova scored higher than 64% of companies evaluated by MarketBeat, and ranked 346th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

LivaNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

LivaNova has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 10.18%

Earnings Growth

Earnings for LivaNova are expected to grow by 10.18% in the coming year, from $2.85 to $3.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LivaNova is -11.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LivaNova is -11.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LivaNova has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.08% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LivaNova has recently increased by 9.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LivaNova does not currently pay a dividend.

Dividend Growth

LivaNova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.08% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LivaNova has recently increased by 9.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.76

News Sentiment

LivaNova has a news sentiment score of 1.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for LivaNova this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for LIVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LivaNova insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.29% of the stock of LivaNova is held by insiders.

Percentage Held by Institutions

97.64% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LIVN Stock Analysis - Frequently Asked Questions

How have LIVN shares performed this year?

LivaNova's stock was trading at $46.31 at the beginning of 2025. Since then, LIVN stock has decreased by 0.4% and is now trading at $46.13.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its earnings results on Wednesday, May, 1st. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.28. The company's revenue was up 12.0% on a year-over-year basis.
Read the conference call transcript.

Who are LivaNova's major shareholders?

LivaNova's top institutional shareholders include Central Pacific Bank Trust Division (0.01%). Insiders that own company stock include Damien Mcdonald, Daniel Jeffrey Moore and Francesco Bianchi.
View institutional ownership trends.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LivaNova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LivaNova investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 5/01/2024
• Today: 7/06/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LIVN
• CIK: 1639691
• Web: www.livanova.com
• Phone: 442033250660
• Fax: 281-218-9332
• Employees: 2,900
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $59.29
• High Stock Price Target: $64.00
• Low Stock Price Target: $55.00
• Potential Upside/Downside: +28.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 16.19
• P/E Growth: N/A
• Net Income: $63.23 million
• Net Margins: -17.41%
• Pretax Margin: -15.14%
• Return on Equity: 13.67%
• Return on Assets: 6.68%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 1.58
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $1.25 billion
• Price / Sales: 2.01
• Cash Flow: $4.24 per share
• Price / Cash Flow: 10.88
• Book Value: $24.31 per share
• Price / Book: 1.90

Miscellaneous

• Outstanding Shares: 54,530,000
• Free Float: 54,368,000
• Market Cap: $2.52 billion
• Optionable: Optionable
• Beta: 0.90